Torrent On Acquisition And Licensing Strategy, Vonoprazan Trajectory
FY25: 5-10 Product Approvals Expected In US
Amid deals activity in India, Torrent Pharma executives spelt out their acquisition expectations and licensing strategy while an in-licensed Takeda brand did well in Q1 of FY25. The US growth trajectory is seen determined by five to ten product approvals expected this fiscal.
